Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D81YNE
|
|||
| Drug Name |
CFI-402257
|
|||
| Synonyms |
1610759-22-2; CHEMBL4442392; CHEMBL4469414; SCHEMBL16729234; SCHEMBL17182976; SCHEMBL17190272; SCHEMBL22046104; SCHEMBL22875551; BCP31204; EX-A2577; BDBM50512456; BDBM50533120; NSC800888; ZINC669678971; CS-6527; NSC-800888; SB19839; AK685452; HY-101340; CFI 402257; CFI402257; J3.619.525H; 1610677-37-6; N-cyclopropyl-4-(7-((((1r,3r)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide; N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Treadwell Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H30N6O3
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)C2=C3N=C(C=C(N3N=C2)NCC4CC(C4)(C)O)OC5=CN=CC=C5)C(=O)NC6CC6
|
|||
| InChI |
1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,30,36H,6-7,12-14H2,1-2H3,(H,32,35)
|
|||
| InChIKey |
PMQUGSPFUBGJCZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dual specificity protein kinase TTK (MPS1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell cycle | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| WikiPathways | Retinoblastoma (RB) in Cancer | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02792465) A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.